Business Segments · Capital expenditures, gross
Biotechnology — Capital expenditures, gross
Danaher Biotechnology — Capital expenditures, gross increased by 22.3% to $115.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 1.7%, from $117.00M to $115.00M. Over 4 years (FY 2021 to FY 2025), Biotechnology — Capital expenditures, gross shows relatively stable performance with a -1.0% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2020
Last reportedQ4 2025
How to read this metric
Higher spending suggests investment in future growth, while lower spending may indicate a focus on cash preservation.
Detailed definition
The total cash outflow for the acquisition or maintenance of long-term physical assets within the biotechnology segment....
Peer comparison
Standard capital investment metric across manufacturing and life science peers.
Metric ID:
dhr_segment_biotechnology_capital_expenditures_grossHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $96.25M | $96.25M | $96.25M | $101.25M | $101.25M | $101.25M | $101.25M | $104.25M | $104.25M | $104.25M | $104.25M | $102.00M | $111.00M | $117.00M | $117.00M | $81.00M | $80.00M | $94.00M | $115.00M |
| QoQ Change | — | +0.0% | +0.0% | +5.2% | +0.0% | +0.0% | +0.0% | +3.0% | +0.0% | +0.0% | +0.0% | -2.2% | +8.8% | +5.4% | +0.0% | -30.8% | -1.2% | +17.5% | +22.3% |
| YoY Change | — | — | — | — | +5.2% | +5.2% | +5.2% | +3.0% | +3.0% | +3.0% | +3.0% | -2.2% | +6.5% | +12.2% | +12.2% | -20.6% | -27.9% | -19.7% | -1.7% |
Range$80.00M – $117.00M
CAGR+4.0%
Avg YoY Growth-0.9%
Median YoY Growth+3.0%
Current Streak2 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Danaher's biotechnology — capital expenditures, gross?
- Danaher (DHR) reported biotechnology — capital expenditures, gross of $115.00M in Q4 2025.
- How has Danaher's biotechnology — capital expenditures, gross changed year-over-year?
- Danaher's biotechnology — capital expenditures, gross decreased by 1.7% year-over-year, from $117.00M to $115.00M.
- What is the long-term trend for Danaher's biotechnology — capital expenditures, gross?
- Over 4 years (2021 to 2025), Danaher's biotechnology — capital expenditures, gross has grown at a -1.0% compound annual growth rate (CAGR), from $385.00M to $370.00M.
- What does biotechnology — capital expenditures, gross mean?
- Total spending on physical assets and infrastructure for the biotechnology segment.